Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06538623
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-31
Brief Title:
Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion HAIC Followed by 5-FULV HAIC or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Single-arm Open-label Clinical Study of Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion HAIC Followed by 5-FluorouracilLeucovorin HAIC or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer After First-line Therapy Failure With AG Regimen
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study explores the efficacy and safety of oxaliplatin combined with irinotecan liposome injection II via hepatic arterial infusion HAIC followed by sequential treatment with 5-FULV HAIC or oral administration of S-1 in patients with liver metastasis from pancreatic cancer after the failure of first-line treatment with the AG regimen This research aims to accumulate more clinical evidence and treatment options for second-line therapy in metastatic pancreatic cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None